Itopride therapy for functional dyspepsia:A meta-analysis  

作　　者：Xuan Huang Bin Lv Shuo Zhang Yi-Hong Fan Li-Na Meng 

机构地区：[1]Department of Gastroenterology,the First Affiliated Hospital,Zhejiang Chinese Medical University

出　　处：《World Journal of Gastroenterology》2012年第48期7371-7377,共7页世界胃肠病学杂志（英文版）

基　　金：Supported by The Natural Science Foundation of Zhejiang Province of China,No. LY12H29002;Traditional Chinese Medicine Science Foundation of Zhejiang Province of China,No. 2011ZB032

摘　　要：AIM:To evaluate the therapeutic effects of itopride vs other drugs(placebo,domperidone,mosapride) for functional dyspepsia(FD).METHODS:Randomized controlled trials(RCTs) of itopride for FD were retrieved from databases.Relevant information was extracted and analyzed,using the relative risk(RR) and weighted mean deviation,as appropriate.A random or fixed effect model was used,based on the heterogeneity of the included articles,and visual inspection of funnel plots was used to evaluate publication bias.RESULTS:Nine RCTs enrolling 2620 FD cases were included;1372 cases received itopride treatment and 1248 cases received placebo or other drugs(control groups).Compared with control groups,itopride had superior RR values of 1.11 [95%CI:(1.03,1.19),P = 0.006],1.21 [95%CI:(1.03,1.44),P = 0.02],and1.24 [95%CI:(1.01,1.53),P = 0.04] for global patient assessment,postprandial fullness,and early satiety,respectively.For the Leeds Dyspepsia Questionnaire score,the weighted mean deviation was-1.38 [95%CI:(-1.75,-1.01),P < 0.01].The incidence of adverse effects was similar in the itopride and control groups.The funnel plots for all indicators showed no evidence of publication bias.CONCLUSION:Itopride has good efficacy in terms of global patients assessment,postprandial fullness,and early satiety in the treatment of patients with FD and shows a low rate of adverse reactions.Itopride can greatly improve FD syndromes-score.AIM：To evaluate the therapeutic effects of itopride vs other drugs（placebo,domperidone,mosapride） for functional dyspepsia（FD）.METHODS：Randomized controlled trials（RCTs） of itopride for FD were retrieved from databases.Relevant information was extracted and analyzed,using the relative risk（RR） and weighted mean deviation,as appropriate.A random or fixed effect model was used,based on the heterogeneity of the included articles,and visual inspection of funnel plots was used to evaluate publication bias.RESULTS：Nine RCTs enrolling 2620 FD cases were included;1372 cases received itopride treatment and 1248 cases received placebo or other drugs（control groups）.Compared with control groups,itopride had superior RR values of 1.11 [95%CI：（1.03,1.19）,P = 0.006],1.21 [95%CI：（1.03,1.44）,P = 0.02],and1.24 [95%CI：（1.01,1.53）,P = 0.04] for global patient assessment,postprandial fullness,and early satiety,respectively.For the Leeds Dyspepsia Questionnaire score,the weighted mean deviation was-1.38 [95%CI：（-1.75,-1.01）,P 〈 0.01].The incidence of adverse effects was similar in the itopride and control groups.The funnel plots for all indicators showed no evidence of publication bias.CONCLUSION：Itopride has good efficacy in terms of global patients assessment,postprandial fullness,and early satiety in the treatment of patients with FD and shows a low rate of adverse reactions.Itopride can greatly improve FD syndromes-score.

关 键 词：Itopride Functional dyspepsia Meta-analysis Randomized controlled trials Prokinetic agents 

分 类 号：R57[医药卫生—消化系统]